HUA-XIN X LIAO

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies
    Ben Jiang Ma
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Pathog 7:e1002200. 2011
  2. pmc Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    J Virol 87:4185-201. 2013
  3. pmc Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    Hua Xin Liao
    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Nature 496:469-76. 2013
  4. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
  5. pmc Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:2237-49. 2011
  6. ncbi request reprint Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 165:148-57. 2000
  7. ncbi request reprint Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF
    Hua Xin Liao
    Department of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Box 3258, Durham, NC 27710, USA
    Vaccine 20:2396-403. 2002
  8. pmc Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites
    Jae Sung Yu
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Vaccine Immunol 14:886-93. 2007
  9. pmc Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions
    S Moses Dennison
    Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 83:10211-23. 2009
  10. pmc Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production
    Anthony R Geonnotti
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS Res Hum Retroviruses 26:279-91. 2010

Detail Information

Publications34

  1. pmc Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies
    Ben Jiang Ma
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Pathog 7:e1002200. 2011
    ....
  2. pmc Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    J Virol 87:4185-201. 2013
    ....
  3. pmc Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    Hua Xin Liao
    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Nature 496:469-76. 2013
    ..These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination...
  4. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  5. pmc Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:2237-49. 2011
    ..These data suggest that the majority of gp41-binding antibodies produced after acute HIV-1 infection are cross-reactive responses generated by stimulating memory B cells that have previously been activated by non-HIV-1 antigens...
  6. ncbi request reprint Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 165:148-57. 2000
    ..w. CD45RA isoforms. Although the presence of the CCR5 Delta 32 mutation down-regulates HIV-1 infection of thymocytes, the functional CD45RA polymorphism does not alter the susceptibility of thymocytes to HIV-1 infection in vitro...
  7. ncbi request reprint Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF
    Hua Xin Liao
    Department of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Box 3258, Durham, NC 27710, USA
    Vaccine 20:2396-403. 2002
    ....
  8. pmc Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites
    Jae Sung Yu
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Vaccine Immunol 14:886-93. 2007
    ..However, rBCG could prime for a protein boost by HIV-1 envelope protein. Thus, rBCG can serve as a vector for induction of anti-HIV-1 consensus Env cellular responses at mucosal sites...
  9. pmc Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions
    S Moses Dennison
    Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 83:10211-23. 2009
    ..These data have important implications for the design and use of peptide-liposome conjugates as immunogens for the induction of MPER-neutralizing antibodies...
  10. pmc Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production
    Anthony R Geonnotti
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS Res Hum Retroviruses 26:279-91. 2010
    ..The results also highlight the need to use endotoxin-free specimens to avoid artifacts when assessing HIV-1-specific neutralizing antibodies in PBMC-based assays...
  11. pmc Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection
    Marc C Levesque
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Med 6:e1000107. 2009
    ..While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effect of early HIV-1 on these cells...
  12. pmc Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 207:763-76. 2010
    ..The release of these beta-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes...
  13. pmc Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins
    Jae Sung Yu
    Departments of Medicine, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Virol Methods 168:248-50. 2010
    ..Thus, while MAbs 15H10 and 6D11 are indeed EBOV GP specific, MAb 17A3 is an alpha-2-macroglobulin MAb...
  14. pmc Is developing an HIV-1 vaccine possible?
    Barton F Haynes
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Curr Opin HIV AIDS 5:362-7. 2010
    ..This review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success...
  15. doi request reprint Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region
    Nathan I Nicely
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Nat Struct Mol Biol 17:1492-4. 2010
    ..We show that unlike 2F5, 13H11 binds to a well-defined helical MPER structure that is consistent with the structure of gp41 in a post-fusion six-helix bundle conformation...
  16. pmc B cell responses to HIV-1 infection and vaccination: pathways to preventing infection
    Barton F Haynes
    Duke Human Vaccine Institute and the Duke Center for AIDS Research, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Trends Mol Med 17:108-16. 2011
    ....
  17. pmc Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein
    Feng Gao
    Department of Medicine, Duke University Medical Center, 112 Research Park III, Research Dr, Box 3347, Durham, NC 27710, USA
    J Virol 79:1154-63. 2005
    ..Thus, the computer-generated "consensus" env genes are capable of expressing envelope glycoproteins that retain the structural, functional, and immunogenic properties of wild-type HIV-1 envelopes...
  18. ncbi request reprint Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity
    Feng Gao
    The Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Expert Rev Vaccines 3:S161-8. 2004
    ..It is biologically functional and preserves antigenicity similar to contemporary Env proteins. Most importantly, the group M consensus Env immunogen can elicit both T- and B-cell responses to wild-type HIV-1 isolates...
  19. pmc Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins
    Hua Xin Liao
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Virol 78:5270-8. 2004
    ....
  20. pmc Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance
    Laurent Verkoczy
    Duke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:181-6. 2010
    ..These features are consistent with elimination of 2F5 HC autoreactivity by additional negative selection mechanism(s) in the periphery...
  21. pmc Role of HIV membrane in neutralization by two broadly neutralizing antibodies
    S Munir Alam
    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 106:20234-9. 2009
    ..These results bear directly on strategies for rational design of HIV-1 envelope immunogens...
  22. ncbi request reprint Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates
    Barton F Haynes
    Department of Medicine and Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Virology 345:44-55. 2006
    ....
  23. ncbi request reprint Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor
    Jae Sung Yu
    Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, United States
    J Virol Methods 137:219-28. 2006
    ..Thus, polyclonal and monoclonal antibodies can be used in combination to identify and differentiate both human and non-human primate EBOV GPs...
  24. pmc A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Virology 353:268-82. 2006
    ..Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes...
  25. pmc Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  26. ncbi request reprint Centralized HIV-1 envelope immunogens and neutralizing antibodies
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham NC 27710, USA
    Curr HIV Res 5:572-7. 2007
    ....
  27. pmc Murine CD7 shares antigenic cross-reactivity with HSP-60
    Brandon A Howard
    Departments of Medicine, Duke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA
    Hybridoma (Larchmt) 27:81-9. 2008
    ..These data demonstrated molecular mimicry of mCD7 with HSP-60, and leave open the question of surface expression of mCD7...
  28. pmc Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
    Georgia D Tomaras
    Duke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 82:12449-63. 2008
    ..These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection...
  29. ncbi request reprint Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  30. pmc Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Virology 394:91-8. 2009
    ..Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers...
  31. pmc High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, United States
    J Virol Methods 158:171-9. 2009
    ..These Ig gene expression cassettes constitute a highly efficient strategy for rapid expression of Ig genes for high-throughput screening and analysis without cloning...
  32. pmc Comparison of multiple vaccine vectors in a single heterologous prime-boost trial
    Brice Barefoot
    Duke Human Vaccine Institute, Duke University School of Medicine, DU Medical Center, 102 Research Drive, Durham, NC 27710, USA
    Vaccine 26:6108-18. 2008
    ..Comparative data such as those presented here are critical to efforts to generate protective vaccines for emerging infectious diseases as well as for biothreat agents...
  33. pmc High throughput functional analysis of HIV-1 env genes without cloning
    Jennifer L Kirchherr
    Duke Human Vaccine Institute and Center for HIV AIDS Vaccine Immunology, Department of Medicine, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, Durham, NC 27710, USA
    J Virol Methods 143:104-11. 2007
    ..The new pPCR method eliminates cloning, transformation, and plasmid DNA preparation steps in the generation of HIV-1 pseudovirions. This allows for quick analysis of multiple env genes from HIV-1 infected individuals...
  34. pmc A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro
    Woohyun Yoon
    Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    AIDS 24:155-7. 2010
    ....